JOSÉ M. LÓPEZ, M.D.; CARLOS B. FARDELLA, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Bromocriptine, acting as a dopaminergic agonist, reduces the secretion of prolactin by the pituitary gland (1) and can also reduce the size of prolactinomas through a reduction of cytoplasmatic cell volume and tumoral cell population (2, 3). The usual dose of bromocriptine as a treatment for prolactinomas is from 5.0 to 10.0 mg/24 h. We report the case of a man with a prolactinoma who drastically reduced his serum prolactin level when treated with minimal doses of bromocriptine.
A 55-year-old man was seen in December 1983 because of lack of libido, but was otherwise asymptomatic. His serum
LÓPEZ JM, FARDELLA CB. Bromocriptine Therapy and Hyperprolactinemia. Ann Intern Med. 1987;106:909–910. doi: 10.7326/0003-4819-106-6-909_2
Download citation file:
Published: Ann Intern Med. 1987;106(6):909-910.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use